Dr. Gianni Colotti, Ph.D.
Position: Senior Researcher
Istituto di Biologia e Patologia Molecolari IBPM CNR
Italian National Research Council CNR; P.le A. Moro 5, 00185 Roma
WORK EXPERIENCE
Since 2020: Senior Researcher, CNR.
2017: qualification Full Professor (National Scientific Abilitation, 05-E1 Biochemistry)
1996-2020: Research Scientist at the Institute of Molecular Biology and Pathology, CNR (National Research Council).
1994-1995: Post-doc fellowship in Medical Sciences, University of Rome "La Sapienza".
1993-1994: CNR fellowship in Molecular Biology and Biotechnology
1991-1993: Program in Molecular Medicine and Department of Biochemistry and Molecular Biology, University of Massachusetts Medical Center, Worcester, Massachusetts.
1990-1993: Ph. D. in Biochemistry, Dept. Biochemical Sciences, Sapienza University of Rome, Rome, Italy
EDUCATION
1989: degree in Biological Sciences (with honors), Sapienza University of Rome, Italy.
1993: Ph.D. in Biochemistry, Sapienza University of Rome
ACTIVITIES
Since 2020: Member of the Council of Institute, IBPM CNR
2018-2019: Member Board of Directors, Società Italiana Vescicole Extracellulari (EVIta).
Since 2018: Co-founder and member of the Italian Society for Extracellular Vesicles - Società Italiana Vescicole Extracellulari (EVIta).
Since 2018: Member of NeuroNet, network CNR on Neurosciences.
Since 2017: Member of the European Huntington’s Disease Network.
Since 2016: Co-founder of Thena Biotech.
Since 2016: member of SIB (Italian Society of Biochemistry).
Since 2013: Member of LeishRIIP at Institute Pasteur, for research on leishmaniasis.
Since 2012: Co-founder of the qPMO (Quality and Project Management OpenLab) CNR.
Since 2011: Member of the Scientific Committee of the Biocrystal Facility CNR.
2011-today: Co-founder and member of the Biocrystal Facility CNR.
Since 2012: Co-founder and member of the Foresight Group CNR.
2010-2015: Coordinator for Technology Transfer for IBPM CNR.
TEACHING
Since 2017: Member of the Teaching Board, Ph.D. School in Biochemistry, Rome.
2011: Course "Bioinformatics for biology", Univ. L'Aquila, Italy
2010: Course "Bioinformatics for Molecular Biologists", CNR.
2007: Course "Bioinformatics for Biologists", CNR.
2005: Course "Applications of Bioinformatics in Molecular and Structural Biology” CNR.
2005: Course "Bioinformatics for Molecular Biologists", Ph.D. in Cellular Biology, Rome, Italy.
1997-2010: Course of Molecular Biology, School of Specialization in Pathological Anatomy, Faculty of Medicine, University "Sapienza", Rome, Italy.
1997-2008: lecturer of Molecular Biology, First School of Specialization in Oncology, Faculty of Medicine, University "Sapienza", Rome, Italy.
Skills covered
Gianni Colotti coordinates a group of study on the chemical-physical properties of proteins, and in particular:
- analysis of structure-function protein relationships
- drug targeting and drug discovery against Leishmaniasis
- calcium signalling in cancer
- drug delivery
- drug discovery against cancer and neurodegenerative diseases.
Member of the Editorial Board of the journals: Scientific Reports; Mini Reviews in Medicinal Chemistry; Frontiers in Microbiology; Frontiers in Molecular Biosciences; Frontiers in Cell and Developmental Biology; ISRN Structural Biology.
Reviewer for National Science Foundation, European FP7, Israel Science Foundation, Austrian Science Foundation, MRC Cambridge, Agence Nationale de la Recherche France (ANR), Joint Projects Università Verona, Czech Health Research Council.
Invited speaker at several international meetings and conferences (15 invited lectures in international meetings in the last 7 years).
Research responsibilities:
2023-2025: Scientific Coordinator Operative Unit UO2, Project PRIN 2022: PROGETTI DI RICERCA DI RILEVANTE INTERESSE NAZIONALE – Prot. 2022HYF8KS.
Tryp4Leish: a One Health approach for the structure-based discovery of anti-leishmania agents interfering with the trypanothione-based defense system in trypanosomatids.
2018-2022: Italian Substitute, COST (European Cooperation in Science and Technology) Harmonising standardisation strategies to increase efficiency and competitiveness of European life-science research (CHARME), WG4, WG5.
2013-2019: Coordinator of Work Package (WP2): Flagship Project Nanomax: NADINE “Nanotechnology-based Diagnostics In Neurological diseases and Experimental oncology”
2012-2017. Scientific Coordinator of Operative Unit, Project: “Pemphigus vulgaris as a paradigm of autoantibody-mediated organ-specific autoimmune disorder: pathophysiology and novel tools for diagnosis and therapy” Ricerca finalizzata 2010, Min. Salute. Progetto RF-2010-2309790.
2012-2015. Coordinator of Operative Unit: “Quality methods for Design of Experiments in Scientific Research”, in the Framework of the FaReBio di Qualità Project: Quality and Project Management OpenLab: qPMO CNR. Prot. IEOS – CNR N. 0000623 del 24/4/2013.
2010-2012: Coordinator of the project: “Molecular complexes of sorcin and E-Syt1 in the generation and regulation of calcium-dependent cellular functions”, CNR-CSIC.
2008-2011: Scientific Coordinator of operative Unit, PRIN (Research Programs of National Interest) 2007 “Supramolecular complexes of sorcin in the generation and regulation of Calcium-dependent cellular functions”.
102 peer reviewed publications on international journals, 5 book chapters.
H-index: 38: Google Scholar; 33: Scopus.
SELECTED PUBLICATIONS (last 6 years) (*: corresponding author)
1. Saccoliti F, Angiulli G, Pupo G, Pescatori L, Madia VN, Messore A, Colotti G, Fiorillo A, Scipione L, Gramiccia M, Di Muccio T, Di Santo R, Costi R, Ilari A.
“Inhibition of Leishmania infantum trypanothione reductase by diaryl sulfide derivatives”.
J Enzyme Inhib Med Chem. 2017; 32(1):304-310.
2. Ilari A, Fiorillo A, Genovese I, Colotti G*.
Polyamine-trypanothione pathway: an update.
Future Med Chem. 2017 Jan; 9(1):61-77.
3. Poser E, Genovese I, Masciarelli S, Bellissimo T, Fazi F, Colotti G*.
Surface Plasmon Resonance: A Useful Strategy for the Identification of Small Molecule Argonaute 2 Protein Binders.
Methods Mol Biol. 2017; 1517:223-237.
4. Bellissimo T, Masciarelli S, Poser E, Genovese I, Del Rio A, Colotti G, Fazi F.
“Small Molecules Targeting the miRNA-Binding Domain of Argonaute 2: From Computer-Aided Molecular Design to RNA Immunoprecipitation”.
Methods Mol Biol. 2017; 1517:211-221.
5. Mosca L, Falvo E, Ceci P, Poser E, Genovese I, Guarguaglini G, Colotti G*
“Use of Ferritin-Based Metal-Encapsulated Nanocarriers as Anticancer Agents”
Applied Sciences 2017, 7, 101. doi:10.3390/app7010101
6. Morea V, Bidollari E, Colotti G, Fiorillo A, Rosati J, De Filippis L, Squitieri F, Ilari A.
"Glucose transportation in the brain and its impairment in Huntington disease: one more shade of the energetic metabolism failure?”
Amino Acids. 2017, 49, 7, 1147-1157. doi: 10.1007/s00726-017-2417-2.
7: Asteriti IA, Daidone F, Colotti G, Rinaldo S, Lavia P, Guarguaglini G, Paiardini A.
“Identification of small molecule inhibitors of the Aurora-A/TPX2 complex.”
Oncotarget. 2017 Mar 31. doi: 10.18632/oncotarget.16738.
8: Genovese I, Fiorillo A, Ilari A, Masciarelli S, Fazi F, Colotti G*.
“Binding of doxorubicin to Sorcin impairs cell death and increases drug resistance in cancer cells.”
Cell Death and Disease. 2017. 8, 7, e2950. doi: 10.1038/cddis.2017.342.
9. Genovese I, Ilari A, Assaraf YG, Fazi F, Colotti G*.
“Not only P-glycoprotein: amplification of the ABCB1-containing chromosome region 7q21 confers multidrug resistance upon cancer cells by coordinated overexpression of an assortment of resistance-related proteins.”
Drug Resistance Updates. 2017, 32, 23-46. doi: 10.1016/j.drup.2017.10.003
10: Ferrara M, Sessa G, Fiore M, Bernard F, Asteriti IA, Cundari E, Colotti G, Ferla S, Desideri M, Buglioni D, Triscuoglio D, Del Bufalo D, Brancale A, Degrassi F.
“Small molecules targeted to the microtubule-Hec1 interaction inhibit cancer cell growth through microtubule stabilization”
Oncogene. 2018, 37(2):231-240. doi: 10.1038/onc.2017.320.
11: Colotti G*, Fiorillo A, Ilari A.
“Metal-and metalloid-containing drugs for the treatment of trypanosomatid diseases.”
Frontiers in biosciences. 2018. 23, 954-966. doi: 10.2741/4628.
12: De Cola A, Franceschini M, Di Matteo A, Colotti G, Celani R, Clemente E, Ippoliti R, Cimini AM, Dhez AC, Vallée B, Raineri F, Cascone I, Destouches D, De Laurenzi V, Courty J, Federici L.
“N6L pseudopeptide interferes with nucleophosmin protein-protein interactions and sensitizes leukemic cells to chemotherapy.”
Cancer Letters. 2018, 412, 272-282. doi: 10.1016/j.canlet.2017.10.038
13: Falvo E, Malagrinò F, Arcovito A, Fazi F, Colotti G, Tremante E, Di Micco P, Braca A, Opri R, Giuffrè A, Fracasso G, Ceci P.
“The presence of glutamate residues on the PAS sequence of the stimuli-sensitive nano-ferritin improves in vivo biodistribution and mitoxantrone encapsulation homogeneity.”
J Control Release. 2018 Feb 20;275:177-185. doi: 10.1016/j.jconrel.2018.02.025.
14: Ortalli M, Ilari A, Colotti G, De Ionna I, Battista T, Bisi A, Gobbi S, Rampa A, Di Martino RMC, Gentilomi GA, Varani S, Belluti F
“Identification of chalcone-based antileishmanial agents targeting trypanothione reductase”
European journal of medicinal chemistry 152, 527-541. doi: 10.1016/j.ejmech.2018.04.057.
15. Ilari A, Genovese I, Fiorillo F, Battista T, De Ionna I, Fiorillo A, Colotti G*.
“Toward a Drug Against All Kinetoplastids: From LeishBox to Specific and Potent Trypanothione Reductase Inhibitors.”
Mol Pharm. 2018 Jun 27. doi: 10.1021/acs.molpharmaceut.8b00185.
16. Genovese I, Ilari A, Battista T, Chiarini V, Fazi F, Fiorillo A, Colotti G.*
“Molecular bases of Sorcin-dependent resistance to chemotherapeutic agents”
Cancer Drug Resist. 2018; 1:164-180. doi:10.20517/cdr.2018.10.
17. Kahremany S, Zhenin M, Shenberger Y, Maimoun D, Colotti G, Arad M, Shainberg A, Senderowitz H, Ruthstein S, Gruzman A.
“Peptide-based development of PKA inhibitors”
New Journal of Chemistry 2018, 42, 23:18585-18597. doi: 10.1039/C8NJ01732H.
18. Turcano L, Torrente E, Missineo A, Andreini M, Gramiccia M, Di Muccio T, Genovese I, Fiorillo A, Harper S, Bresciani A, Colotti G*, Ilari A.
“Identification and binding mode of a novel Leishmania Trypanothione reductase inhibitor from high throughput screening”
PLOS Neglected Tropical Diseases 2018, 12,11:e0006969. doi:10.1371/journal.pntd.0006969
19. Pippa S, Mannironi C, Licursi V, Bombardi L, Colotti G, Cundari E, Mollica A, Coluccia A, Naccarato V, La Regina G, Silvestri R, Negri R.
“Small Molecule Inhibitors of KDM5 Histone Demethylases Increase the Radiosensitivity of Breast Cancer Cells Overexpressing JARID1B”
Molecules 2019, 1, 9:1739. doi:10.3390/molecules24091739.
20. Chiarini V, Tossavainen H, Sharma V, Colotti G*.
“NMR structure of a non-conjugatable, ADP-ribosylation associated, ubiquitin-like domain from Tetrahymena thermophila polyubiquitin locus”
Biochimica et Biophysica Acta (BBA)-General Subjects 2019, 1863, 4:749. doi: 10.1016/j.bbagen.2019.01.014.
21. Colotti G*, Saccoliti F, Gramiccia M, Di Muccio T, Prakash J, Yadav S, Kumar Dubey V, Vistoli G, Battista T, Mocci S, Fiorillo A, Bibi A, Madia VN, Messore A, Costi R, Di Santo R, Ilari A.
“Structure-guided approach to identify a novel class of anti-leishmaniasis diaryl sulfide compounds targeting the trypanothione metabolism”
Amino Acids 2019, 1-13. doi: 10.1007/s00726-019-02731-4.
22. Rinaldi T, Colotti G*.
“Use of organoids in medicinal chemistry: challenges on ethics and biosecurity”
Future Medicinal Chemistry 2019, 11 (10), 1087-1090. doi: 10.4155/fmc-2018-0341.
23. Carbo M, Brandi V, Pascarella G, Staid DS, Colotti G, Polticelli F, Ilari A, Morea V.
“Bioinformatics analysis of Ras homologue enriched in the striatum, a potential target for Huntington's disease therapy”
International journal of molecular medicine 2019, 4373. doi: 10.3892/ijmm.2019.4373.
24. Battista T, Fiorillo A, Chiarini V, Genovese I, Ilari A, Colotti G*.
“Roles of Sorcin in Drug Resistance in Cancer: One Protein, Many Mechanisms, for a Novel Potential Anticancer Drug Target.
Cancers (Basel). 2020 Apr 6;12(4):887. doi: 10.3390/cancers12040887.
25. Caroselli S, Zwergel C, Pirolli A, Sabatino M, Xu Z, Kirsch G, Mai A, Colotti G, Altieri F, Canipari R, Valente S, Ragno R.
“Discovery of the First Human Arylsulfatase A Reversible Inhibitor Impairing Mouse Oocyte Fertilization”.
ACS Chem Biol. 2020 Jun 19;15(6):1349-1357. doi: 10.1021/acschembio.9b00999.
26. Genovese I, Carotti A, Ilari A, Fiorillo A, Battista T, Colotti G, Ivarsson Y.
“Profiling calcium-dependent interactions between Sorcin and intrinsically disordered regions of human proteome.
Biochim Biophys Acta Gen Subj. 2020 Aug;1864(8):129618. doi:10.1016/j.bbagen.2020.129618.
27. Perli E, Pisano A, Pignataro MG, Campese AF, Pelullo M, Genovese I, de Turris V, Ghelli AM, Cerbelli B, Giordano C, Colotti G, Morea V, d'Amati G.
“Exogenous peptides are able to penetrate human cell and mitochondrial membranes, stabilize mitochondrial tRNA structures, and rescue severe mitochondrial defects.
FASEB J. 2020 Jun;34(6):7675-7686. doi: 10.1096/fj.201903270R.
28. Battista T, Colotti G, Ilari A, Fiorillo A.
“Targeting Trypanothione Reductase, a Key Enzyme in the Redox Trypanosomatid Metabolism, to Develop New Drugs against Leishmaniasis and Trypanosomiases”.
Molecules. 2020 Apr 21;25(8):1924. doi: 10.3390/molecules25081924.
29. Colotti G*, Rinaldi T.
“The central role of gut microbiota in drug metabolism and personalized medicine”.
Future Med Chem. 2020 May 29. doi: 10.4155/fmc-2020-0023.
30. Turcano L, Battista T, De Haro ET, Missineo A, Alli C, Paonessa G, Colotti G, Harper S, Fiorillo A, Ilari A, Bresciani A.
“Spiro-containing derivatives show antiparasitic activity against Trypanosoma brucei through inhibition of the trypanothione reductase enzyme”.
PLoS Negl Trop Dis. 2020 May 21;14(5):e0008339. doi: 10.1371/journal.pntd.0008339.
31. Mascia A, Cirafici AM, Bongiovanni A, Colotti G, Lacerra G, Di Carlo M, Digilio FA, Liguori GL, Lanati A, Kisslinger A.
“A failure mode and effect analysis (FMEA)-based approach for risk assessment of scientific processes in non-regulated research laboratories
Accreditation And Quality Assurance. 2020. doi: 10.1007/s00769-020-01441-9.
32. Genovese I, Giamogante F, Barazzuol L, Battista T, Fiorillo A, Vicario M, D'Alessandro G, Cipriani R, Limatola C, Rossi D, Sorrentino V, Poser E, Mosca L, Squitieri F, Perluigi M, Arena A, van Petegem F, Tito C, Fazi F, Giorgi C, Calì T, Ilari A, Colotti G*.
“Sorcin is an early marker of neurodegeneration, Ca2+ dysregulation and endoplasmic
reticulum stress associated to neurodegenerative diseases.”
Cell Death Dis. 2020 Oct 15;11(10):861. doi: 10.1038/s41419-020-03063-y.
33. Flego M, Colotti G, Ascione A, Dupuis ML, Petrucci E, Riccioni R, Andreotti M, Raggi C, Boe A, Barca S, Gellini M, Vella S, Mallano A.
“Isolation and preliminary characterization of a human 'phage display'-derived antibody against neural adhesion molecule-1 antigen interfering with fibroblast growth factor receptor-1 binding.”
Hum Antibodies. 2020 Oct 23. doi: 10.3233/HAB-200431.
34. Mosca L, Ilari A, Fazi F, Assaraf YG, Colotti G*.
“Taxanes in cancer treatment: Activity, chemoresistance and its overcoming.”
Drug Resist Updat. 2021 Jan;54:100742. doi: 10.1016/j.drup.2020.100742.
35. Chiarini V, Fiorillo A, Camerini S, Crescenzi M, Nakamura S, Battista T, Guidoni L, Colotti G*, Ilari A.
“Structural basis of ubiquitination mediated by protein splicing in early Eukarya.”
Biochim Biophys Acta Gen Subj. 2021 May;1865(5):129844. doi: 10.1016/j.bbagen.2021.129844.
36. Battista T, Pascarella G, Staid DS, Colotti G, Rosati J, Fiorillo A, Casamassa A, Vescovi AL, Giabbai B, Semrau MS, Fanelli S, Storici P, Squitieri F, Morea V, Ilari A.
“Known Drugs Identified by Structure-Based Virtual Screening Are Able to Bind Sigma-1 Receptor and Increase Growth of Huntington Disease Patient-Derived Cells.”
Int J Mol Sci. 2021 Jan 28;22(3):1293. doi: 10.3390/ijms22031293.
37. Colotti G, Failla CM, Lacal PM, Ungarelli M, Ruffini F, Di Micco P, Morea V.
“Neuropilin-1 is required for endothelial cell adhesion to soluble vascular endothelial growth factor receptor 1”.
FEBS Journal, 2022, 15(1), 183-198. doi:10.1111/febs.16119.
38. Fiorillo A, Morea V, Colotti G, Ilari A.
“Huntingtin Ubiquitination Mechanisms and Novel Possible Therapies to Decrease the Toxic Effects of Mutated Huntingtin”.
J. Pers. Med. 2021, 11(12), 1309; doi:10.3390/jpm11121309
39. Valentini E, D'Aguanno S, Di Martile M, Montesano C, Ferraresi V, Patsilinakos A, Sabatino M, Antonini L, Valente S, Mai A, Colotti G, Ragno R, Trisciuoglio D, Del Bufalo D.
“Targeting the anti-apoptotic Bcl-2 family proteins: machine learning virtual screening and biological evaluation of new small molecules”.
Theranostics 2022, 12(5), 2427-2444; doi:10.7150/thno.64233.
40. Di Risola D, Ricci D, Marrocco I, Giamogante F, Grieco M, Francioso A, Vasco-Vidal A, Mancini P, Colotti G*, Mosca L, Altieri F.
“ERp57 chaperon protein protects neuronal cells from Aβ-induced toxicity”.
J Neurochem. 2022; 162(4):322-336. doi: 10.1111/jnc.15655.
41. Fiorillo A, Colotti G, Exertier C, Liuzzi A, Seghetti F, Salerno A, Caciolla J, Ilari A.
"Innovative Approach for a Classic Target: Fragment Screening on Trypanothione Reductase Reveals New Opportunities for Drug Design”.
Front Mol Biosci. 2022; 9:900882. doi: 10.3389/fmolb.2022.900882.
42. Battista T, Federico S, Brogi S, Pozzetti L, Khan T, Butini S, Ramunno A, Fiorentino E, Orsini S, Di Muccio T, Fiorillo A, Exertier C, Di Risola D, Colotti G*, Gemma
S, Ilari A, Campiani G.
“Optimization of Potent and Specific Trypanothione Reductase Inhibitors: A Structure Based Drug Discovery Approach”.
ACS Infect Dis. 2022; 8(8):1687-1699. doi: 10.1021/acsinfecdis.2c00325.
43. Tramonti A, Ghatge MS, Babor JT, Musayev FN, di Salvo ML, Barile A, Colotti G, Giorgi A, Paredes SD, Donkor AK, Al Mughram MH, de Crécy-Lagard V, Safo MK, Contestabile R.
“Characterization of the Escherichia coli pyridoxal 5'-phosphate homeostasis protein (YggS): Role of lysine residues in PLP binding and protein stability”.
Protein Sci. 2022; 31(11):e4471. doi: 10.1002/pro.4471.
44. Madia VN, Ialongo D, Patacchini E, Exertier C, Antonelli L, Colotti G, Messore A, Tudino V, Saccoliti F, Scipione L, Ilari A, Costi R, Di Santo R.
“Inhibition of Leishmania infantum Trypanothione Reductase by New Aminopropanone Derivatives Interacting with the NADPH Binding Site”.
Molecules. 2023; 28(1):338. doi: 10.3390/molecules28010338.
45. Pascarella G, Antonelli L, Narzi D, Battista T, Fiorillo A, Colotti G, Guidoni L, Morea V, Ilari A.
“Investigation of the Entry Pathway and Molecular Nature of σ1 Receptor Ligands”.
Int J Mol Sci. 2023 Mar 28;24(7):6367. doi: 10.3390/ijms24076367.
46. Zwergel C, Aventaggiato M, Garbo S, Di Bello E, Fassari B, Noce B, Castiello C, Lambona C, Barreca F, Rotili D, Fioravanti R, Schmalz T, Weyand M, Niedermeier A, Tripodi M, Colotti G, Steegborn C, Battistelli C, Tafani M, Valente S, Mai A.
"Novel 1,4-Dihydropyridines as Specific Binders and Activators of SIRT3 Impair Cell Viability and Clonogenicity, and Downregulate Hypoxia-Induced Targets in Cancer Cells"
Journal of Medicinal Chemistry 2023, 66(14): 9622-9641. doi: 10.1021/acs.jmedchem.3c00337.
47. Tito C, Genovese I, Giamogante F, Benedetti A, Miglietta S, Barazzuol L, Cristiano L, Iaiza A, Carolini S, De Angelis L, Masciarelli S, Nottola SA, Familiari G, Petrozza V, Lauriola M, Tamagnone L, Ilari A, Calì T, Valdivia HH, Valdivia CR, Colotti G*, Fazi F.
“Sorcin promotes migration in cancer and regulates the EGF-dependent EGFR signaling Pathways”.
Cellular and Molecular Life Sciences 2023;80(8):202. doi: 10.1007/s00018-023-04850-4
48. Valentini E, Di Martile M, Brignone M, Di Caprio M, Manni I, Chiappa M, Sergio I, Chiacchiarini M, Bazzichetto C, Conciatori F, D'Aguanno S, D'Angelo C, Ragno R, Russillo M, Colotti G, Felli M, Damia G, Del Bufalo D, Marchesi F, Bellone M, Dal Piaz F.
"Bcl-2 family inhibitors sensitize human cancer models to therapy".
Cell Death and Disease, 2023; 14(7):441. doi: 10.1038/s41419-023-05963-1.
49. Mattioli R, Ilari A, Colotti B, Mosca L, Fazi F, Colotti G*
" Doxorubicin and other anthracyclines in cancers: activity, chemoresistance and its overcoming".
Molecular Aspects of Medicine, 2023; 93:101205. doi:10.1016/j.mam.2023.101205
50: Fracasso G, Falvo E, Tisci G, Sala G, Colotti G, Cingarlini S, Tito C, Bibbo S, Frusteri C, Tremante E, Giordani E, Giacomini P, Ceci P.
Widespread in vivo efficacy of The-0504: A conditionally-activatable nanoferritin for tumor-agnostic targeting of CD71-expressing cancers.
Heliyon. 2023 Oct 6;9(10):e20770. doi: 10.1016/j.heliyon.2023.e20770.